The price-to-earnings ratio for Astrazeneca plc ADR (NASDAQ: AZN) is 28.96x, which is above its average ratio. Moreover, the 36-month beta value for AZN is 0.40. Analysts have varying opinions on the stock, with 6 analysts rating it as a “buy,” 5 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for AZN is 3.10B and currently, short sellers hold a 0.20% of that float. On May 06, 2025, AZN’s average trading volume was 6.20M shares.
AZN) stock’s latest price update
Astrazeneca plc ADR (NASDAQ: AZN) has seen a decline in its stock price by -0.48 in relation to its previous close of 72.44. However, the company has experienced a 3.09% gain in its stock price over the last five trading sessions. reuters.com reported 2025-05-02 that Anglo-Swedish drugmaker AstraZeneca on Friday said its inhaler therapy Breztri Aerosphere met all the main goals of two late-stage trials in patients with uncontrolled asthma.
AZN’s Market Performance
Astrazeneca plc ADR (AZN) has experienced a 3.09% rise in stock performance for the past week, with a -2.48% drop in the past month, and a 3.19% rise in the past quarter. The volatility ratio for the week is 1.83%, and the volatility levels for the past 30 days are at 2.83% for AZN. The simple moving average for the past 20 days is 5.24% for AZN’s stock, with a -1.98% simple moving average for the past 200 days.
Analysts’ Opinion of AZN
Many brokerage firms have already submitted their reports for AZN stocks, with Exane BNP Paribas repeating the rating for AZN by listing it as a “Outperform.” The predicted price for AZN in the upcoming period, according to Exane BNP Paribas is $75 based on the research report published on April 15, 2025 of the current year 2025.
AZN Trading at -0.51% from the 50-Day Moving Average
After a stumble in the market that brought AZN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -17.78% of loss for the given period.
Volatility was left at 2.83%, however, over the last 30 days, the volatility rate increased by 1.83%, as shares surge +5.30% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -2.87% lower at present.
During the last 5 trading sessions, AZN rose by +3.09%, which changed the moving average for the period of 200-days by -9.62% in comparison to the 20-day moving average, which settled at $68.50. In addition, Astrazeneca plc ADR saw 10.03% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for AZN
Current profitability levels for the company are sitting at:
- 0.19 for the present operating margin
- 0.81 for the gross margin
The net margin for Astrazeneca plc ADR stands at 0.14. The total capital return value is set at 0.14. Equity return is now at value 19.81, with 7.45 for asset returns.
Based on Astrazeneca plc ADR (AZN), the company’s capital structure generated 0.44 points at debt to capital in total, while cash flow to debt ratio is standing at 0.41. The debt to equity ratio resting at 0.77. The interest coverage ratio of the stock is 7.95.
Currently, EBITDA for the company is 15.44 billion with net debt to EBITDA at 1.49. When we switch over and look at the enterprise to sales, we see a ratio of 4.54. The receivables turnover for the company is 4.15for trailing twelve months and the total asset turnover is 0.52. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.90.
Conclusion
To wrap up, the performance of Astrazeneca plc ADR (AZN) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
